辉瑞-BioNTech新冠疫苗首剂接种后过敏反应及严重过敏反应监测
截至2020年12月23日,美国接种1,893,360剂辉瑞-BioNTech新冠疫苗首剂,VAERS收到4,393例(0.2%)不良事件报告,其中21例判定为严重过敏反应,发生率为每百万剂11.1例。多数严重过敏反应发生于有过敏史者,中位发病时间13分钟,随访者均恢复或出院。CDC建议接种前筛查禁忌证、备好严重过敏反应救治物资并实施接种后观察。
要点
- 首剂接种后严重过敏反应发生率为每百万剂11.1例,多数有过敏史。
- 严重过敏反应中位发病时间13分钟,接种后应留观。
- 接种点需备好严重过敏反应救治物资,首选肌注肾上腺素。
核心结论
- 辉瑞-BioNTech新冠疫苗首剂接种后严重过敏反应罕见,发生率为每百万剂11.1例,但需做好接种前筛查和接种后观察。
研究设计与样本
- 基于美国VAERS被动监测系统,分析2020年12月14日至23日接种辉瑞-BioNTech新冠疫苗首剂后的不良事件报告。
主要发现
- 截至2020年12月23日,美国共接种1,893,360剂首剂,VAERS收到4,393例(0.2%)不良事件报告。
- 175例报告被筛选为可能严重过敏反应,其中21例判定为严重过敏反应,发生率为每百万剂11.1例。
- 21例严重过敏反应中17例有过敏或过敏反应史,7例有严重过敏反应史。
- 严重过敏反应从接种到症状发生的中位间隔为13分钟(范围2-150分钟)。
- 20例有随访信息者均恢复或出院回家;86例为非严重过敏的过敏反应,61例为非过敏性不良事件,7例仍在调查中。
关键数值与推荐
- CDC发布mRNA新冠疫苗使用的更新临时临床考虑,以及严重过敏反应潜在管理的临时考虑。
- 接种前应筛查禁忌证和注意事项,接种点应备有严重过敏反应救治物资,实施接种后观察期,出现严重过敏反应体征和症状时立即肌注肾上腺素治疗。
临床怎么用
- 接种前筛查过敏史等禁忌证和注意事项。
- 接种点备齐严重过敏反应救治物资,并实施接种后观察。
- 发现严重过敏反应体征或症状时立即肌注肾上腺素。
局限性
- 被动监测系统可能存在报告偏倚和漏报,部分病例仍在调查中,随访信息不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As of January 3, 2021, a total of 20,346,372 cases of coronavirus disease 2019 (COVID-19) and 349,246 associated deaths have been reported in the United States. Long-term sequalae of COVID-19 over the course of a lifetime currently are unknown; however, persistent symptoms and serious complications are being reported among COVID-19 survivors, including persons who initially experience a mild acute illness.* On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 vaccine to prevent COVID-19, administered as 2 doses separated by 21 days. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine (1); initial doses were recommended for health care personnel and long-term care facility residents (2). As of December 23, 2020, a reported 1,893,360 first doses of Pfizer-BioNTech COVID-19 vaccine had been administered in the United States, and reports of 4,393 (0.2%) adverse events after receipt of Pfizer BioNTech COVID-19 vaccine had been submitted to the Vaccine Adverse Event Reporting System (VAERS). Among these, 175 case reports were identified for further review as possible cases of severe allergic reaction, including anaphylaxis. Anaphylaxis is a life-threatening allergic reaction that does occur rarely after vaccination, with onset typically within minutes to hours (3). Twenty-one cases were determined to be anaphylaxis (a rate of 11.1 per million doses administered), including 17 in persons with a documented history of allergies or allergic reactions, seven of whom had a history of anaphylaxis. The median interval from vaccine receipt to symptom onset was 13 minutes (range = 2-150 minutes). Among 20 persons with follow-up information available, all had recovered or been discharged home. Of the remaining case reports that were determined not to be anaphylaxis, 86 were judged to be nonanaphylaxis allergic reactions, and 61 were considered nonallergic adverse events. Seven case reports were still under investigation. This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphylaxis allergic reactions, after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine during December 14-23, 2020, in the United States. CDC has issued updated interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States (4) and interim considerations for preparing for the potential management of anaphylaxis (5). In addition to screening for contraindications and precautions before administering COVID-19 vaccines, vaccine locations should have the necessary supplies available to manage anaphylaxis, should implement postvaccination observation periods, and should immediately treat persons experiencing anaphylaxis signs and symptoms with intramuscular injection of epinephrine (4,5).
引用
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33444297. doi:10.15585/mmwr.mm7002e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。